AFT Pharmaceuticals has announced it has extended its US Maxigesic licensing agreement with Hikma Pharmaceuticals.
The new agreement aims to maximise the commercial and patient care benefits that come with following the intravenous form of the pain relief medicine (marketed as Combogesic IV in the US) in postoperative care with the tablet form of the medicine (Combogesic Rapid).
AFT will now play a greater role in sales and marketing in the US, which is the world's largest pain relief market.
The agreement will see Hikma take over all channels for Combogesic Rapid in the US, allowing both forms of AFT's patented non-opioid medicines to be sold across the entire market.
Around 6% of patients given opioids postoperatively develop opioid dependency.
"We are pleased to have reached this agreement with Hikma," said AFT Managing Director Dr Hartley Atkinson.
"Since the launch of Maxigesic IV last year, feedback from the market is that clinicians wish to follow non-opioid intravenous relief of mild to moderate pain with the tablet therapy - an approach that offers non opioid relief through all stages of recovery."
The above article was sent to subscribers in Pharmacy Daily's issue from 28 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 May 25
